Alebund Pharmaceuticals Completes Patient Enrollment in P-III (RESPOND-2) Trial of AP301 for Hyperphosphatemia

Why It Matters

The enrollment milestone moves AP301 toward regulatory clearance, potentially delivering a new phosphate‑binder option for the large, underserved dialysis population in both the U.S. and China.

Key Takeaways

• Enrollment reached 282 patients, surpassing target of 264
• Trial spans US (138) and China (144) dialysis patients
• Includes double‑blind, open‑label, and withdrawal phases
• China NDA planned after successful Phase I/II data
• FDA accepts trial as sole pivotal for US approval

Pulse Analysis

Hyperphosphatemia is a common complication in patients with end‑stage renal disease on maintenance dialysis, driving vascular calcification, cardiovascular events, and mortality. The global dialysis market, exceeding 500,000 U.S. patients and a similar scale in China, generates over $2 billion annually in phosphate‑binder sales. Existing binders such as sevelamer and calcium acetate have adherence challenges and side‑effect profiles, leaving a therapeutic gap for agents that can more effectively control serum phosphate with fewer gastrointestinal issues. AP301, Alebund’s novel oral binder, aims to fill this void by targeting phosphate absorption pathways with a proprietary formulation.

The RESPOND‑2 Phase III trial marks Alebund’s first multi‑regional pivotal study, enrolling 282 participants—138 in the United States and 144 in China—well above the planned 264. The study design incorporates an eight‑week double‑blind segment, a 24‑week open‑label maintenance period, and a three‑week randomized withdrawal comparing therapeutic versus sub‑therapeutic dosing. This comprehensive approach provides robust efficacy and safety data across diverse ethnic and clinical settings, strengthening the external validity of the results and positioning AP301 for simultaneous regulatory submissions in two of the world’s largest dialysis markets.

Regulatory feedback is already favorable: the U.S. Food and Drug Administration has agreed that the global trial can serve as the single pivotal dataset for U.S. registration, while Alebund is preparing a New Drug Application for the China National Medical Products Administration based on earlier Phase I/II outcomes. If approved, AP301 could capture a sizable share of the phosphate‑binder market, especially given its potential to improve patient adherence and reduce hospitalization costs. Investors will be watching enrollment milestones and upcoming data readouts as key catalysts for Alebund’s valuation.